Related Experiment Video
Updated: Feb 17, 2026

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
Model-Informed Reverse and Forward Translation of Safety Risks in Drug Development
1Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA.
Abstract:
Despite major scientific investments, safety accounts for significant pipeline attrition, especially in late preclinical and early clinical development. Many failures are due to difficulty interpreting safety signals or difficulty optimizing schedules of compounds with narrow therapeutic margins. Model-informed translation can address these challenges, both through "forward" translation of early signals to future scenarios, as well as through "reverse" translation of safety data into mechanistic insight.
More Related Videos
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Preclinical Development: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Discovery: Overview

